Resilience
About Resilience
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives by continuously advancing the science of biopharmaceutical manufacturing and development. For more information, visit www.Resilience.com and follow us on Twitter @IncResilience
Where to Find Us: Biotech Beach | Pharm Country | Genetown | BioNC
18 articles about Resilience
-
Resilience Appoints Bill Marth as President of Services
11/7/2023
National Resilience, Inc. today announced that William S. Marth, RPh., MBA has been appointed to the newly created role of President of Services.
-
October saw a surge of life science job activity with job applications up 65% from last year as well as a number of a significant layoff announcements.
-
Resilience Announces Joint Venture with Lifera to Develop Manufacturing Facility in Saudi Arabia
8/28/2023
National Resilience, Inc. and Lifera have entered into a non-binding term sheet for the development of biopharma manufacturing capacity in Riyadh, Saudi Arabia.
-
Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity
3/24/2023
National Resilience, Inc. (Resilience) today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC).
-
Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca’s Manufacturing Site in West Chester, Ohio
11/29/2022
National Resilience, Inc. (Resilience) and AstraZeneca PLC announced today that the companies will establish a long-term biomanufacturing relationship in support of AstraZeneca’s portfolio.
-
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
-
Resilience Becomes Biomanufacturing Resource Partner for California Institute for Regenerative Medicine
8/23/2022
National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, was named by the California Institute for Regenerative Medicine (CIRM) as one of the initial Industry Resource Partners within its Industry Alliance Program (IAP).
-
Resilience Announces Collaboration to Manufacture and Deliver Biotherapeutics for Rare and Complex Conditions
8/15/2022
National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.
-
The Parker Institute for Cancer Immunotherapy and Resilience Announce Strategic Alliance to Develop Next-Generation Cancer Therapies
6/8/2022
The Parker Institute for Cancer Immunotherapy and National Resilience, Inc. announced the launch of a five-year strategic alliance to develop next-generation cancer therapies generated from PICI’s network of leading immunotherapy research centers.
-
Resilience Announces $625 Million Series D Financing to Expand Network, Bring Innovative Technologies to Biomanufacturing
6/6/2022
Up-round financing follows a previously unannounced $600 million Series C Financing completed in August 2021.
-
Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer
6/2/2022
National Resilience, Inc. and The University of Texas MD Anderson Cancer Center announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer.
-
Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda’s Plasma-Derived Therapies Business Unit
2/15/2022
National Resilience, Inc. today announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit.
-
Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment
2/9/2022
National Resilience, Inc. today announced the U.S. Department of Defense (DOD) has awarded Ology Bioservices, Inc. (Ology), a wholly owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxin.
-
Resilience Acquires SwiftScale Biologics, a Leader in Cell-Free Protein Synthesis Technology
12/2/2021
National Resilience, Inc. (Resilience), a technology focused manufacturing company dedicated to broadening access to complex medicines, today announced the acquisition of SwiftScale Biologics, a San Leandro, California-based company developing cell-free protein synthesis (CFPS) technology.
-
Resilience Joins Forces with Childen’s Hospital of Philadelpia to Develop Next-Generation Biomanufacturing Technologies, Create Impactful Therapies
10/12/2021
National Resilience, Inc. announced a strategic collaboration with Children’s Hospital of Philadelphia ( CHOP ) to implement next-generation biomanufacturing technologies and capabilities aimed at accelerating the creation of impactful therapies and technologies for the benefit of patients.
-
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
9/8/2021
National Resilience, Inc. and Moderna, Inc. today announced an agreement to manufacture drug substance for the Moderna COVID-19 vaccine.
-
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
7/28/2021
National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.
-
Resilience Receives USD $164 Million Investment from the Government of Canada to Modernize and Expand Its Ontario Biomanufacturing Site, Improving Pandemic Preparedness
5/18/2021
National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced that the Government of Canada will invest CAD 199.2 million ($163.8 million), through the Strategic Innovation Fund , in the company’s Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI) to modernize and expand production capacity.